Dentsply Sirona Reports Fourth Quarter and Full Year 2025 Results, Provides Full Year 2026 Outlook

Rhea-AI Summary

Dentsply Sirona (Nasdaq: XRAY) reported Q4 2025 net sales of $961M (+6.2% vs. Q4 2024; constant currency +2.5%) and Q4 adjusted EPS of $0.27. GAAP results included $144M goodwill and intangible impairments, producing a Q4 net loss of ($146M) and diluted loss per share of ($0.74).

Full‑year 2025 net sales were $3.68B (down 3.0%); FY adjusted EPS was $1.60. The company announced a restructuring with ~$55–65M charges, ~$120M annualized savings, elimination of the quarterly dividend, and FY 2026 guidance of $3.5B–$3.6B sales and adjusted EPS $1.40–$1.50.

Positive

• Q4 net sales +6.2% to $961M
• Expected annualized cost savings of $120M
• FY 2026 adjusted EPS guidance of $1.40–$1.50

Negative

• Recorded $144M goodwill and intangible impairments (Q4)
• Full‑year net sales declined 3.0% to $3.68B
• Free cash flow fell to $104M in FY 2025 from $281M
• Elimination of the quarterly dividend; potential shareholder income impact

News Market Reaction – XRAY

+15.50% 2.0x vol

61 alerts

+15.50% Session close to close

+22.7% Peak in 12 min

$2.94B Market Cap

2.0x Rel. Volume

In the Feb 27 session, XRAY gained 15.50%, reflecting a significant positive market reaction. Argus tracked a peak move of +22.7% during that session. Our momentum scanner triggered 61 alerts that day, indicating high trading interest and price volatility. Trading volume was above average at 2.0x the daily average, suggesting increased trading activity.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock surged +15.5% in the session following this news. A strong positive reaction aligns with h...

Analysis

The stock surged +15.5% in the session following this news. A strong positive reaction aligns with how XRAY sometimes traded on earnings when results were viewed as better than feared, despite GAAP losses. The latest update combines Q4 growth, ongoing impairments, and a sizable restructuring targeting $120M annual savings, plus a shift from dividends to buybacks and debt paydown. Investors would still need to monitor execution on the Return-to-Growth plan and whether 2026 targets of $3.5B–$3.6B sales and $1.40–$1.50 adjusted EPS remain intact.

Key Figures

Q4 2025 net sales: $961M (up 6.2% YoY) Q4 2025 net loss: ($146M) Q4 2025 adjusted EPS: $0.27 +5 more

8 metrics

Q4 2025 net sales $961M (up 6.2% YoY) Reported net sales for Q4 2025

Q4 2025 net loss ($146M) GAAP net loss in Q4 2025, driven by impairments

Q4 2025 adjusted EPS $0.27 Non-GAAP EPS for Q4 2025, up 4.9% vs Q4 2024

FY 2025 net sales $3,680M (down 3.0% YoY) Full year 2025 reported net sales vs 2024

FY 2025 adjusted EPS $1.60 (down 4.6% YoY) Full year 2025 non-GAAP EPS vs 2024

2026 sales outlook $3.5B–$3.6B Management net sales guidance for full year 2026

2026 adjusted EPS outlook $1.40–$1.50 Management adjusted EPS guidance for full year 2026

Restructuring savings $120M annually Anticipated annualized cost savings from new restructuring plan

Previous Earnings Reports

5 past events · Latest: Nov 06 (Negative)

Same Type Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Nov 06	Q3 2025 earnings	Negative	-12.7%	Sales declined and large non-cash impairments drove a substantial GAAP net loss.
Aug 07	Q2 2025 earnings	Negative	-3.3%	Revenue fell and a major impairment charge led to a GAAP loss despite EPS uplift.
May 08	Q1 2025 earnings	Positive	+16.3%	Improved margins and higher GAAP net income offset revenue declines and Byte drag.
Feb 27	FY 2024 earnings	Negative	-8.8%	Full-year sales declined and large goodwill impairments produced a steep net loss.
Nov 07	Q3 2024 earnings	Negative	-28.0%	Modest sales growth was overshadowed by a big impairment and reduced FY24 outlook.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent earnings events often triggered sizable moves, with an average one-day reaction of -7.3%, typically aligning with the tone of the results, especially when impairments and guidance changes were involved.

Recent Company History

Over the past several quarters, XRAY’s earnings reports have featured recurring themes of revenue pressure, large non-cash impairment charges, and evolving guidance. Prior updates introduced the Return-to-Growth plan, leadership changes, and margin-improvement efforts. Price reactions have frequently been negative, especially when outlooks were revised or sizable impairments were recorded. Today’s Q4/FY25 release and 2026 outlook continue this narrative, combining restructuring, capital allocation changes, and ongoing non-GAAP profitability focus with GAAP losses.

Key Terms

constant currency sales, adjusted EBITDA, adjusted EPS, free cash flow, +1 more

5 terms

constant currency sales financial

"Q4 2025 net sales of $961 million increased 6.2%, constant currency sales increased 2.5%"

Constant currency sales measure a company’s revenue as if exchange rates had not changed over the comparison period, isolating underlying business growth from swings in foreign currencies. For investors, this is like comparing two years’ prices after converting both into the same currency rate so you can see whether sales rose because of real demand and pricing or merely because the local currency moved; it helps assess true operational performance.

adjusted EBITDA financial

"Adjusted EBITDA | | $135 | | $128 | | 5.3 %"

Adjusted EBITDA is a way companies measure how much money they make from their core operations, like running a business, by removing certain costs or income that aren’t part of regular business activities. It helps investors see how well a company is doing without distractions from unusual expenses or gains, making it easier to compare companies or track performance over time.

adjusted EPS financial

"Q4 2025 adjusted EPS of $0.27"

Adjusted earnings per share (adjusted eps) is a measure of a company's profit per share that has been modified to exclude certain one-time or unusual items, such as costs from restructuring or asset sales. It provides a clearer picture of the company’s core performance by removing events that may distort the usual earnings. Investors use adjusted eps to better understand a company's ongoing profitability and compare it more accurately over time.

free cash flow financial

"Free cash flow, a Non-GAAP measure, in the fourth quarter of 2025 was $60 million"

Free cash flow is the amount of money a company has left over after paying all its expenses and investing in its business, like buying equipment or updating facilities. It shows how much cash is available to reward shareholders, pay down debt, or save for future growth. This helps investors understand if a company is financially healthy and able to grow.

View in glossary

non-cash impairment charges financial

"the Company recorded non-cash impairment charges for goodwill and other intangible assets of ($144) million"

Non-cash impairment charges are accounting adjustments that reduce the recorded value of assets on a company's books when their worth has declined, even though the company has not spent any money to make this change. They matter to investors because they signal that some assets may be less valuable than previously thought, potentially indicating financial challenges or future losses for the company.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

News Summary

• Q4 2025 net sales of $961 million increased 6.2%, constant currency sales increased 2.5%
• Q4 2025 reported net loss of ($146) million and diluted loss per share of ($0.74) driven by goodwill and intangible impairments of ($144) million, net of tax
• Q4 2025 adjusted EPS of $0.27
• FY 2026 outlook: net sales in the range of $3.5B to $3.6B; adjusted EPS of $1.40 to $1.50⁽¹⁾
• Announced a restructuring initiative to redirect approximately $120 million annually into the Return-to-Growth Action Plan, prioritizing investments in accelerated innovation, clinical education, and sales team education focused on connected dentistry
• Initiated new capital allocation strategy by eliminating the dividend and redeploying capital toward debt retirement and share repurchases
• Established new agreements with Patterson Dental, Benco Dental, Burkhart Dental Supply, and A-dec
• Launched Surity™ Female External Catheter to enter a new market category in the U.S.
• Appointed three new members to the Board of Directors: James Forbes, former Vice Chairman Investment Bank of Morgan Stanley; Brian McKeon, former CFO of IDEXX Laboratories, Inc.; and Don Zurbay, former CEO of Patterson Dental
  

CHARLOTTE, N.C., Feb. 26, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the “Company”) (Nasdaq: XRAY) today announced its financial results for the fourth quarter and full year of 2025.

“We delivered results in line with our expectations this quarter while making meaningful progress against our clear, focused priorities and strengthening execution across the business,” said Dan Scavilla, President and Chief Executive Officer. “In 2026, we are acting with urgency and accountability on our Return-to-Growth Action Plan - going deeper, moving faster and being bolder to enhance the customer experience, strengthen commercial performance and optimize capital allocation.”

Scavilla continued, “Our restructuring program announced today will allow us to streamline operations, improve efficiency and support a more competitive cost structure, while our decision to eliminate the dividend will enable the redeployment of capital toward share repurchases and debt reduction. These are important steps in our roadmap to drive sustained, profitable growth and deliver meaningful long-term value for our shareholders.”

⁽¹⁾As explained below under Full Year 2026 Outlook, the Company does not provide a forward-looking estimate of earnings on a GAAP basis due to unavailability of certain information.

Q4 2025 and FY 2025 Summary Results (Reported)

(in millions, except per share amount and percentages)		Q4 25		Q4 24		YoY		FY 25		FY 24		YoY
Net Sales		$961		$905		6.2%		$3,680		$3,793		(3.0%)
Gross Profit		$443		$446		(0.5%)		$1,840		$1,958		(6.0%)
Gross Margin		46.2%		49.2%				50.0%		51.6%
Net (Loss) Attributable to Dentsply Sirona		($146)		($430)		NM		($598)		($910)		NM
Diluted (Loss) Per Share1		($0.74)		($2.16)		NM		($3.00)		($4.48)		NM

Q4 2025 and FY 2025 Summary Results (Non-GAAP)

(in millions, except per share amount and percentages)		Q4 25		Q4 24		YoY		FY 25		FY 24		YoY
Constant Currency Sales						2.5%						(4.3%)
Adjusted EBITDA		$135		$128		5.3%		$667		$631		5.6%
Adjusted EBITDA Margin		14.1%		14.2%				18.1%		16.6%
Adjusted EPS		$0.27		$0.26		4.9%		$1.60		$1.67		(4.6%)

NM - not meaningful
Percentages are based on actual values and may not reconcile due to rounding.
^[1] Weighted-average shares outstanding used to calculate diluted loss per share for the fourth quarters of 2025 and 2024 excludes potential dilutive common shares.

Additional Q4 and FY 2025 Commentary

• Q4 2025 net sales of $961 million increased 6.2%, constant currency sales increased 2.5%, including 5.7% driven by Q4 2024 Byte impact and ERP pre-buy
• FY 2025 net sales of $3,680 million decreased (3.0%), constant currency sales decreased (4.3%) including a (1.9%) Byte sales impact

							Percentage Change
Net Sales by Segment	(in millions, except percentages)						Q4 2025 vs. Q4 2024
												United States					Europe					Rest of World
		2025			2024		As Reported1		Constant Currency1			As Reported		Constant Currency			As Reported		Constant Currency			As Reported		Constant Currency
Connected Technology Solutions	$	299		$	293		1.8	%	(1.9	)%		9.0	%	8.5	%		0.9	%	(7.1	)%		(3.2	)%	(3.9	)%
Essential Dental Solutions		372			346		7.8	%	4.0	%		3.7	%	3.5	%		8.6	%	0.1	%		12.0	%	10.8	%
Orthodontic and Implant Solutions		202			185		9.8	%	6.9	%		52.2	%	52.1	%		3.6	%	(3.7	)%		(16.8	)%	(15.3	)%
Wellspect Healthcare		88			81		6.9	%	1.9	%		13.0	%	14.8	%		5.9	%	(0.6	)%		3.6	%	3.4	%
Total	$	961		$	905		6.2	%	2.5	%		14.5	%	14.3	%		4.8	%	(2.9	)%		(0.6	)%	(0.9	)%
(1) Constant currency sales as a Non-GAAP measure are the reported net sales adjusted for the impact of foreign currency changes, which is calculated by translating current period net sales using the comparable prior period’s currency exchange rates. The foreign currency impact is the only reconciling item between as reported and constant currency sales.

Percentages are based on actual values and may not recalculate due to rounding.

							Percentage Change
Net Sales by Segment	(in millions, except percentages)						FY2025 vs. FY2024
												United States					Europe					Rest of World
		2025			2024		As Reported1		Constant Currency1			As Reported		Constant Currency			As Reported		Constant Currency			As Reported		Constant Currency
Connected Technology Solutions	$	1,036		$	1,062		(2.5	)%	(3.8	)%		(12.4	)%	(12.4	)%		5.8	%	1.6	%		(2.8	)%	(2.0	)%
Essential Dental Solutions		1,469			1,454		1.1	%	(0.2	)%		(4.3	)%	(4.4	)%		3.9	%	(0.1	)%		5.4	%	6.3	%
Orthodontic and Implant Solutions		850			973		(12.6	)%	(13.4	)%		(24.6	)%	(24.6	)%		(0.5	)%	(3.7	)%		(8.4	)%	(6.9	)%
Wellspect Healthcare		325			304		6.6	%	3.9	%		2.6	%	4.0	%		6.3	%	2.7	%		35.4	%	36.2	%
Total	$	3,680		$	3,793		(3.0	)%	(4.3	)%		(12.3	)%	(12.3	)%		3.8	%	—	%		(0.6	)%	0.4	%
(1) Constant currency sales as a Non-GAAP measure are the reported net sales adjusted for the impact of foreign currency changes, which is calculated by translating current period net sales using the comparable prior period’s currency exchange rates. The foreign currency impact is the only reconciling item between as reported and constant currency sales.

Percentages are based on actual values and may not recalculate due to rounding.

Cash Flow and Liquidity

Operating cash flow in the fourth quarter of 2025 was $101 million compared to $87 million in the fourth quarter of 2024. Free cash flow, a Non-GAAP measure, in the fourth quarter of 2025 was $60 million, compared to $36 million in the fourth quarter of 2024. Full year operating cash flow in 2025 was $235 million compared to $461 million in 2024. Full year 2025 free cash flow was $104 million, as compared to $281 million in the prior year. In the fourth quarter, the Company paid $32 million in dividends resulting in a total of $128 million returned to shareholders through dividends in 2025. The Company had $326 million of cash and cash equivalents as of December 31, 2025.

Goodwill and Intangible Asset Impairments

In the fourth quarter of 2025, the Company recorded non-cash impairment charges for goodwill and other intangible assets of ($144) million, net of tax, related to the Orthodontic and Implant Solutions and Connected Technology Solutions segments. These impairments were driven by lower-than-expected volumes of equipment, implant, and prosthetic products, as well as lowered near-term forecasts, particularly in the United States.

Restructuring Plan

The Company’s Board of Directors approved a restructuring plan to improve operational performance and drive shareholder value creation. In connection with this plan, the Company expects to incur non-recurring charges in the approximate range of $55 million to $65 million, the majority of which will be expensed and paid in cash in 2026 and 2027. The plan is anticipated to result in approximately $120 million in annualized cost savings. The Company intends to reinvest a portion of the anticipated savings in targeted Return-to-Growth initiatives, including investments in accelerated innovation, clinical education, and sales team education focused on connected dentistry.

New Capital Deployment Strategy

Following a strategic review of its capital allocation priorities, the Company has approved the elimination of its quarterly cash dividend. This action allows the redeployment of capital toward debt retirement and share repurchases, strengthening the balance sheet and accelerating long-term shareholder value creation.

“This decision reflects confidence in our growth outlook and disciplined focus on driving EPS growth, reducing share dilution, and capitalizing on what we believe is a share price that undervalues the long-term potential of Dentsply Sirona,” Scavilla said.

Full Year 2026 Outlook

For the full year 2026, the Company expects net sales to be in the range of $3.5 billion to $3.6 billion. Adjusted EPS⁽¹⁾ is expected to be in the range of $1.40 to $1.50. This outlook reflects management’s current expectations regarding tariffs and trade policies.

Other 2026 outlook assumptions are included in the fourth quarter 2025 earnings presentation posted on the Investors section of the Dentsply Sirona website at https://investor.dentsplysirona.com.

⁽¹⁾ We are unable to present a quantitative reconciliation of our expected earnings per diluted share to expected adjusted earnings per diluted share as we are unable to predict with reasonable certainty and without unreasonable effort, items which may include, but are not limited to, restructuring charges, transformation-related costs, impairment charges, certain tax adjustments, and other significant items. The financial impact of these items is uncertain and is dependent on various factors, including timing, and could be material to our Consolidated Statements of Operations.

Conference Call/Webcast Information
Dentsply Sirona’s management team will host an investor conference call and live webcast on February 26, 2026, at 4:30 pm ET. The live webcast of the investor conference call and a presentation related to the call will be available on the Investors section of the Company’s website at https://investor.dentsplysirona.com.

For those planning to participate on the call, please register at https://register-conf.media-server.com/register/BI8d058a1cea004987bfc35ae1ca390d08. A webcast replay of the conference call will be available on the Investors section of the Company’s website following the call.

About Dentsply Sirona
Dentsply Sirona is the world’s largest diversified manufacturer of professional dental products and technologies, with over a century of innovation and service to the dental industry and patients worldwide. Dentsply Sirona develops, manufactures, and markets a comprehensive solutions offering including dental and oral health products as well as other consumable medical devices under a strong portfolio of world-class brands. Dentsply Sirona’s innovative products provide high-quality, effective and connected solutions to advance patient care and deliver better and safer dental care. Dentsply Sirona is headquartered in Charlotte, North Carolina. The Company’s shares are listed in the United States on Nasdaq under the symbol XRAY. Visit www.dentsplysirona.com for more information about Dentsply Sirona and its products.

Forward-Looking Statements and Associated Risks

All statements in this Press Release that do not directly and exclusively relate to historical facts constitute “forward-looking statements.” Such statements are subject to numerous assumptions, risks, uncertainties and other factors that could cause actual results to differ materially from those described in such statements, many of which are outside of our control, including those described in Part I, Item 1A, “Risk Factors” of the Company's most recent Annual Report on Form 10-K, and any updating information or other factors which may be described in the Company’s other filings with the Securities and Exchange Commission (the “SEC”). No assurance can be given that any expectation, belief, goal or plan set forth in any forward-looking statement can or will be achieved, and readers are cautioned not to place undue reliance on such statements which speak only as of the date they are made. We do not undertake any obligation to update or release any revisions to any forward-looking statement or to report any events or circumstances after the date of this Press Release or to reflect the occurrence of unanticipated events. Investors should understand it is not possible to predict or identify all such factors or risks. As such, you should not consider the risks identified in the Company’s SEC filings to be a complete discussion of all potential risks or uncertainties associated with an investment in the Company.

Contact Information:
Investors:
Wade Moody
Senior Manager, Investor Relations
Investorrelations@dentsplysirona.com

Press:
Marion Par-Weixlberger
Vice President, Corporate Communications, Public Relations & Brand
Publicrelations@dentsplysirona.com

DENTSPLY SIRONA INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(in millions, except per share amounts and percentages)
(unaudited)
	Three Months Ended								Year Ended
	December 31,								December 31,
		2025				2024				2025				2024
Net sales	$	961			$	905			$	3,680			$	3,793
Cost of products sold		518				459				1,840				1,835
Gross profit		443				446				1,840				1,958
Selling, general, and administrative expenses		383				401				1,438				1,605
Research and development expenses		40				42				150				165
Goodwill and intangible asset impairments		153				504				650				1,014
Restructuring costs		6				8				24				53
Operating loss		(139	)			(509	)			(422	)			(879	)
Other income and expenses:
Interest expense, net		22				16				88				69
Other income expense, net		(14	)			(2	)			(24	)			(12	)
Loss before income taxes		(147	)			(523	)			(486	)			(936	)
Provision (benefit) for income taxes		(2	)			(95	)			112				(26	)
Net loss		(145	)			(428	)			(598	)			(910	)
Less: Net income (loss) attributable to noncontrolling interests		1				2				—				—
Net loss attributable to Dentsply Sirona	$	(146	)		$	(430	)		$	(598	)		$	(910	)
Net loss per common share attributable to Dentsply Sirona:
Basic	$	(0.74	)		$	(2.16	)		$	(3.00	)		$	(4.48	)
Diluted	$	(0.74	)		$	(2.16	)		$	(3.00	)		$	(4.48	)
Weighted average common shares outstanding:
Basic		199.6				198.8				199.4				203.2
Diluted		199.6				198.8				199.4				203.2

DENTSPLY SIRONA INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(in millions)
(unaudited)
	December 31, 2025			December 31, 2024
Assets
Current Assets:
Cash and cash equivalents	$	326		$	272
Accounts and notes receivable-trade, net		688			556
Inventories, net		642			564
Prepaid expenses and other current assets		367			354
Total Current Assets		2,023			1,746
Property, plant and equipment, net		861			766
Operating lease right-of-use assets, net		139			136
Identifiable intangible assets, net		974			1,207
Goodwill, net		1,148			1,597
Other noncurrent assets		284			301
Total Assets	$	5,429		$	5,753
Liabilities and Equity
Current Liabilities:
Accounts payable	$	300		$	241
Accrued liabilities		700			754
Income taxes payable		30			45
Notes payable and current portion of long-term debt		313			549
Total Current Liabilities		1,343			1,589
Long-term debt		2,015			1,586
Operating lease liabilities		93			91
Deferred income taxes		94			129
Other noncurrent liabilities		544			415
Total Liabilities		4,089			3,810
Total Equity		1,340			1,943
Total Liabilities and Equity	$	5,429		$	5,753

DENTSPLY SIRONA INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS (in millions) (unaudited)
	Year Ended December 31,
		2025				2024
Cash flows from operating activities:
Net loss	$	(598	)		$	(910	)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation		141				133
Amortization of intangible assets		211				216
Goodwill impairment		525				773
Intangible asset impairment		125				241
Deferred income taxes		30				(136	)
Stock-based compensation expense		33				39
Other non-cash (income) expense		(10	)			(9	)
Loss (gain) on disposal of property, plant and equipment		—				19
Changes in operating assets and liabilities:
Accounts and notes receivable-trade, net		(91	)			104
Inventories, net		(17	)			17
Prepaid expenses and other current assets		(7	)			38
Other noncurrent assets		(7	)			(5	)
Accounts payable		11				(30	)
Accrued liabilities		(74	)			(39	)
Income taxes		(32	)			38
Other noncurrent liabilities		(5	)			(28	)
Net cash provided by operating activities	$	235			$	461
Cash flows from investing activities:
Capital expenditures		(131	)			(180	)
Cash received on derivative contracts		10				1
Cash paid on derivative contracts		(14	)			(12	)
Other investing activities, net		3				(6	)
Net cash used in investing activities	$	(132	)		$	(197	)
Cash flows from financing activities:
Proceeds from long-term borrowings		553				1
Cash paid for deferred financing costs		(16	)			—
Repayments on long-term borrowings		(147	)			(88	)
(Repayments) proceeds on other short-term borrowings, net		(336	)			177
Proceeds from 364-day bridge loan		435				—
Repayment of 364-day bridge loan		(435	)			—
Cash paid for treasury stock		—				(250	)
Cash dividends paid		(128	)			(126	)
Other financing activities, net		(6	)			(16	)
Net cash used in financing activities	$	(80	)		$	(302	)
Effect of exchange rate changes on cash and cash equivalents		31				(24	)
Net decrease in cash and cash equivalents		54				(62	)
Cash and cash equivalents at beginning of period		272				334
Cash and cash equivalents at end of period	$	326			$	272
Supplemental disclosures of cash flow information:
Interest paid, net of amounts capitalized	$	66			$	91
Income taxes paid, net of refunds		71				74
Non-cash investing activities:
Change in accounts payable related to capital expenditures	$	37			$	8
Exchange of inventory for naming rights		14				—

Supplemental Information – Reconciliation of GAAP to Non-GAAP Financial Measures

We supplement the reporting of our financial information determined under accounting principles generally accepted in the United States (“GAAP”) with certain non-GAAP financial measures, including percentage sales growth in constant currency; adjusted gross profit; adjusted gross profit as a percent of net sales (“Adjusted Gross Margin”); adjusted operating income; adjusted operating income as a percent of net sales (“Adjusted Operating Margin”); adjusted earnings before interest expense, income taxes, depreciation and amortization (“Adjusted EBITDA”); Adjusted EBITDA as a percent of net sales (“Adjusted EBITDA Margin”); adjusted net income (loss); adjusted earnings (loss) per diluted share (“Adjusted EPS”); and Free Cash Flow. These non-GAAP financial measures are used by the Company to measure its performance and management believes these non-GAAP financial measures provide meaningful information to assist investors and shareholders in understanding our financial results and assessing our prospects for future performance. Management believes percentage sales growth in constant currency and the other adjusted measures described above are important indicators of our operations because they exclude items that may not be indicative of or are unrelated to our core operating results and provide a baseline for analyzing trends in our underlying businesses. Management uses these non-GAAP financial measures for reviewing the operating results of reportable business segments and analyzing potential future business trends in connection with our budget process and bases certain management incentive compensation on these non-GAAP financial measures.

The Company has defined the non-GAAP measures used by management as follows:

• Constant Currency: reported net sales adjusted for the impact of foreign currency changes, which is calculated by translating current period net sales using the comparable period's foreign currency exchange rates.
• Adjusted Operating Income and Margin: Adjusted operating income is computed by excluding the following items from operating income (loss) as reported in accordance with US GAAP. Adjusted operating margin is calculated by dividing adjusted operating income by net sales.
  • Business combination-related costs: costs related to consummating and integrating acquired businesses, as well as net gains and losses related to disposed businesses. Costs include the post-acquisition roll-off of fair value adjustments recorded related to business combinations, except for amortization expense of purchased intangible assets noted below.
  • Restructuring-related charges and other costs: costs related to the implementation of restructuring initiatives, including but not limited to, severance costs, facility closure costs, and lease and contract termination costs, as well as related professional service costs associated with these restructuring initiatives and global transformation activity. Other costs include gains and losses on the sale of property, legal settlements, executive separation costs, write-offs of inventory as a result of product rationalization, and changes in accounting principles recorded within the period. This category also includes costs related to investigations and associated legal cases and remediation activities, which primarily include legal, accounting and other professional service fees, as well as turnover and other employee-related costs.
  • Goodwill and intangible asset impairments: include charges related to goodwill and intangible asset impairments.
  • Amortization of purchased intangible assets: includes the periodic amortization expense related to purchased intangible assets, which are recorded at fair value.
  • Fair value and credit risk adjustments: include the non-cash mark-to-market changes in fair value associated with pension assets and obligations, the credit risk component of hedging instruments, contingent consideration from past acquisitions, and equity-method investments.
• Adjusted Gross Profit and Margin: gross profit excluding the impact of any of the above adjustments that affect either net sales or cost of sales. Adjusted gross margin is calculated by dividing adjusted gross profit by net sales.
• Adjusted Net Income (Loss): net income (loss) as reported in accordance with US GAAP, adjusted to exclude the items identified above, as well as the related income tax impacts of those items. The income tax effect of each pre-tax adjustment was determined based on the tax rate of the jurisdiction in which the related pre-tax adjustment was recorded. Additionally, net income is adjusted for other tax-related adjustments such as discrete or significant adjustments to valuation allowances and other uncertain tax positions, final settlement of income tax audits, discrete tax items resulting from the implementation of restructuring initiatives, the windfall or shortfall relating to exercise of employee stock-based compensation, any difference between the interim and annual effective tax rate, and adjustments relating to prior periods.
• Adjusted EBITDA and Margin: in addition to the adjustments described above in arriving at adjusted net income, adjusted EBITDA is computed by further excluding any remaining interest expense, net, income tax expense, depreciation and amortization. Adjusted EBITDA margin is calculated by dividing adjusted EBITDA by net sales.
• Adjusted Earnings (Loss) Per Diluted Share: computed by dividing adjusted earnings (loss) attributable to Dentsply Sirona stockholders by the diluted weighted average number of common shares outstanding.
• Free Cash Flow: net cash provided by operating activities minus capital expenditures during the same period.

Because non-GAAP financial measures are not standardized, it may not be possible to compare these financial measures with other companies' non-GAAP financial measures having the same or similar names. These adjusted financial measures should not be considered in isolation or as a substitute for the most directly comparable GAAP financial measures. These non-GAAP financial measures are an additional way of viewing aspects of our operations that, when viewed with our GAAP results and the reconciliations to corresponding GAAP financial measures below, provide a more complete understanding of our business. We strongly encourage investors and shareholders to review our financial statements and publicly-filed reports in their entirety and not to rely on any single financial measure.

The following reconciles the non-GAAP financial measures discussed above with the most directly comparable GAAP financial measures. The weighted-average diluted shares outstanding used in the calculation of adjusted net earnings per diluted share are the same as those used in the calculation of reported net earnings per diluted share for the respective period. The weighted-average diluted shares outstanding used in the calculation of adjusted net loss per diluted share excludes potential dilutive common shares.

DENTSPLY SIRONA INC. AND SUBSIDIARIES (in millions, except per share amounts and percentages) (unaudited)
A reconciliation of selected items as reported in the Condensed Consolidated Statements of Operations to adjusted Non-GAAP financial statements items are as follows:
Three Months Ended December 31, 2025		Gross Profit				Operating (Loss) Income				Net (Loss) Income Attributable to Dentsply Sirona (a)				Diluted EPS
Reported		$	443			$	(139	)		$	(146	)		$	(0.74	)
Reported percent net sales			46.2	%			(14.5	%)
Non-GAAP Adjustments:
Amortization of Purchased Intangible Assets			33				56				41				0.21
Restructuring-Related Charges and Other Costs			2				15				6				0.04
Goodwill and Intangible Asset Impairments			—				153				144				0.72
Business Combination-Related Costs and Fair Value Adjustments			1				1				1				—
Income Tax-Related Adjustments			—				—				9				0.04
Adjusted		$	479			$	86			$	55			$	0.27
Adjusted percent net sales			49.8	%			8.9	%
Weighted average common shares outstanding used in calculating diluted GAAP net loss per common share															199.6
Weighted average common shares outstanding used in calculating diluted Non-GAAP net income per common share															200.4
(a) The total tax expense on the Non-GAAP adjustments totals $24 million which is inclusive of the $9 million income tax-related adjustment above.

^{Percentages are based on actual values and may not reconcile due to rounding.}

Three Months Ended December 31, 2024		Gross Profit				Operating (Loss) Income				Net (Loss) Income Attributable to Dentsply Sirona (a)				Diluted EPS
Reported		$	446			$	(509	)		$	(430	)		$	(2.16	)
Reported percent net sales			49.2	%			(56.2	%)
Amortization of Purchased Intangible Assets			30				54				40				0.20
Restructuring-Related Charges and Other Costs			1				45				36				0.18
Goodwill and Intangible Asset Impairments			—				504				370				1.86
Business Combination-Related Costs and Fair Value Adjustments			—				2				2				—
Income Tax-Related Adjustments			—				—				33				0.18
Adjusted		$	477			$	96			$	51			$	0.26
Adjusted percent net sales			52.8	%			10.5	%
Weighted average common shares outstanding used in calculating diluted GAAP net loss per common share															198.8
Weighted average common shares outstanding used in calculating diluted Non-GAAP net income per common share															199.3
(a) The tax expense on the Non-GAAP adjustments totals $124 million, which is inclusive of the $33 million income tax-related adjustment above.

^{Percentages are based on actual values and may not reconcile due to rounding.}

DENTSPLY SIRONA INC. AND SUBSIDIARIES (in millions, except per share amounts and percentages) (unaudited)
Twelve Months Ended December 31, 2025		Gross Profit				Operating (Loss) Income				Net (Loss) Income Attributable to Dentsply Sirona (a)				Diluted EPS (b)
Reported		$	1,840			$	(422	)		$	(598	)		$	(3.00	)
Reported percent net sales			50.0	%			(11.5	%)
Amortization of Purchased Intangible Assets			126				211				155				0.78
Restructuring-Related Charges and Other Costs			3				61				44				0.22
Goodwill and Intangible Asset Impairments			—				650				620				3.10
Business Combination-Related Costs and Fair Value Adjustments			2				8				6				0.03
Fair Value and Credit Risk Adjustments			—				—				1				0.01
Income Tax-Related Adjustments			—				—				92				0.46
Adjusted		$	1,971			$	508			$	320			$	1.60
Adjusted percent of net sales			53.6	%			13.8	%
Weighted average common shares outstanding used in calculating diluted GAAP net loss per common share															199.4
Weighted average common shares outstanding used in calculating diluted Non-GAAP net income per common share															200.1
(a) The total tax expense on the Non-GAAP adjustments totals $9 million, which is inclusive of the $92 million income tax-related adjustment above.
(b) EPS based on year-to-date actual values and may not reconcile to quarter-to-date totals due to rounding.

^{Percentages are based on actual values and may not reconcile due to rounding.}

Twelve Months Ended December 31, 2024		Gross Profit				Operating (Loss) Income				Net (Loss) Income Attributable to Dentsply Sirona (a)				Diluted EPS
Reported		$	1,958			$	(879	)		$	(910	)		$	(4.48	)
Reported percent net sales			51.6	%			(23.2	%)
Amortization of Purchased Intangible Assets			122				216				159				0.78
Restructuring-Related Charges and Other Costs			6				136				106				0.53
Goodwill and Intangible Asset Impairments			—				1,014				870				4.27
Business Combination-Related Costs and Fair Value Adjustments			2				4				3				0.01
Fair Value and Credit Risk Adjustments			—				—				2				0.01
Income Tax-Related Adjustments			—				—				111				0.55
Adjusted		$	2,088			$	491			$	341			$	1.67
Adjusted percent net sales			55.0	%			12.9	%
Weighted average common shares outstanding used in calculating diluted GAAP net loss per common share															203.2
Weighted average common shares outstanding used in calculating diluted Non-GAAP net income per common share															203.8
(a) The total tax expense on the Non-GAAP adjustments totals $121 million, which is inclusive of the $111 million income tax-related adjustment above.

^{Percentages are based on actual values and may not reconcile due to rounding.}

DENTSPLY SIRONA INC. AND SUBSIDIARIES (in millions, except per share amounts and percentages) (unaudited)
Reconciliations of reported net (loss) income attributable to Dentsply Sirona to adjusted EBITDA and margin are as follows:
		Three Months Ended December 31,
(in millions)			2025				2024
Net loss attributable to Dentsply Sirona		$	(146	)		$	(430	)
Interest expense, net			22				16
Income tax benefit			(2	)			(95	)
Depreciation(1)			36				31
Amortization of purchased intangible assets			56				54
Restructuring-related charges and other costs			10				45
Goodwill and intangible asset impairments			153				504
Business combination-related costs and fair value adjustments			1				2
Fair value and credit risk adjustments			5				1
Adjusted EBITDA		$	135			$	128
Net sales		$	961			$	905
Adjusted EBITDA margin			14.1	%			14.2	%

		Year Ended December 31,
(in millions)			2025				2024
Net loss attributable to Dentsply Sirona		$	(598	)		$	(910	)
Interest expense, net			88				69
Income tax benefit			112				(26	)
Depreciation(1)			138				126
Amortization of purchased intangible assets			211				216
Restructuring-related charges and other costs			57				136
Goodwill and intangible asset impairments			650				1,014
Business combination-related costs and fair value adjustments			8				4
Fair value and credit risk adjustments			1				2
Adjusted EBITDA		$	667			$	631
Net sales		$	3,680			$	3,793
Adjusted EBITDA margin			18.1	%			16.6	%

(1) Excludes those depreciation-related amounts which were included as part of the business combination-related adjustments and Restructuring-related charges and other costs.
^{Percentages are based on actual values and may not reconcile due to rounding.}

DENTSPLY SIRONA INC. AND SUBSIDIARIES (in millions, except per share amounts and percentages) (unaudited)
A reconciliation of free cash flow for the three months ended December 31, 2025 and 2024 is as follows:
		Three Months Ended December 31,
(in millions)			2025				2024
Net cash provided by operating activities		$	101			$	87
Capital expenditures			(41	)			(51	)
Free cash flow			60				36

.

A reconciliation of free cash flow for the year ended December 31, 2025 and 2024 is as follows:

		Year Ended December 31,
(in millions)			2025				2024
Net cash provided by operating activities		$	235			$	461
Capital expenditures			(131	)			(180	)
Free cash flow			104				281

FAQ

What were Dentsply Sirona (XRAY) Q4 2025 sales and adjusted EPS?

Q4 2025 sales were $961 million and adjusted EPS was $0.27. According to the company, constant currency sales rose 2.5% and adjusted EBITDA was $135 million, with GAAP results impacted by non‑cash impairments.

Why did XRAY report a Q4 2025 net loss of ($146M)?

The Q4 net loss of ($146 million) was driven by $144 million of goodwill and intangible impairments. According to the company, impairments reflected lower equipment and implant volumes and reduced near‑term U.S. forecasts.

What is Dentsply Sirona’s full‑year 2026 outlook for sales and adjusted EPS (XRAY)?

For FY 2026, XRAY expects net sales of $3.5B–$3.6B and adjusted EPS of $1.40–$1.50. According to the company, this outlook incorporates current expectations for tariffs and trade policy effects.

How will XRAY’s elimination of the dividend affect capital allocation?

Eliminating the quarterly dividend lets XRAY redeploy capital to debt reduction and share repurchases. According to the company, the change aims to strengthen the balance sheet and accelerate long‑term shareholder value creation.

What are the expected costs and savings from Dentsply Sirona’s restructuring plan?

The company expects non‑recurring restructuring charges of about $55–$65 million and anticipates approximately $120 million in annualized cost savings. According to the company, most charges will be expensed and paid in 2026–2027.